Key terms
About XGN
Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest XGN news
May 14
7:37am ET
Exagen price target raised to $7 from $5 at Cantor Fitzgerald
May 14
7:36am ET
Exagen’s Strong Q1 Earnings and Growth Potential Justify Buy Rating
May 14
7:21am ET
Cantor Fitzgerald Sticks to Their Buy Rating for Exagen (XGN)
May 13
7:05pm ET
Buy Rating Affirmed for Exagen Amid Strong Sales Growth and Promising Outlook
May 13
6:55pm ET
Exagen Outperforms: A Strong Buy on Rising Revenues, Margins, and Innovative Growth Prospects
May 13
8:04am ET
Exagen sees FY24 revenue at least $55M, consensus $54.16M
May 13
8:04am ET
Exagen reports Q1 EPS (19c), consensus (36c)
Apr 26
8:42am ET
Exagen Inc Board Reshuffle and New Class I Director Appointment
Apr 26
8:39am ET
Exagen to reduce size of board to seven from nine
Apr 09
7:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 20
5:56am ET
Buy Rating Affirmed for Exagen on Strong Financials and Strategic Growth Initiatives
Mar 19
2:00am ET
Exagen’s Challenge: Strengthening Financial Controls to Restore Confidence and Secure Growth
Mar 18
7:05pm ET
Exagen’s Strong Q4 Performance and Positive Outlook Justify Buy Rating
Mar 18
1:49pm ET
Exagen continues to execute on re-acceleration strategy, says Canaccord
Mar 18
8:03am ET
Exagen sees FY24 revenue $54M, consensus $54.13M
Mar 18
8:02am ET
Exagen reports Q4 EPS (31c), consensus (43c)
No recent press releases are available for XGN
XGN Financials
Key terms
Ad Feedback
XGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
XGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range